H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Argenx to $595 from $494 and keeps a Buy rating on the shares. The chronic inflammatory demyelinating polyneuropathy readout proves Vyvgart “is the gift that keeps on giving,” the analyst tells investors in a research note. For Q2, Vyvgart product net sales once again surpassed estimates, the firm adds. It believes Argenx’s “strong” financial position should also accelerate development of ARGX-117 and ARGX-119.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARGX:
- argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
- argenx announces full exercise of underwriters’ option to purchase additional ADSs
- Biotech Alert: Searches spiking for these stocks today
- Argenx 1.581M share Secondary priced at $490.00
- argenx raises $1.1 billion in gross proceeds in a global offering